Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | ME2 | P23368 | 1/20 | 0.61 |
| ▸ | ME1 | P48163 | 1/20 | 0.61 |
| ▸ | ME3 | Q16798 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492483 | 0.98 | NPC1 (0.69) | NPC1TDP1L3MBTL1HSD11B1ALDH1A1 | |
| SCHEMBL8599235 | 0.98 | NPC1 (0.69) | NPC1TDP1L3MBTL1HSD11B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7223460 | 0.94 | L3MBTL1 (0.65) | NPC1TDP1L3MBTL1HSD11B1ALDH1A1 | |
| SCHEMBL3967794 | 0.92 | HSD11B1 (0.77) | L3MBTL1HSD11B1ALDH1A1KDM4EHPGD | |
| SCHEMBL10722408 | 0.92 | HSD11B1 (0.77) | L3MBTL1HSD11B1ALDH1A1KDM4EHPGD | |
| SCHEMBL5267307 | 0.86 | HSD11B1 (0.70) | L3MBTL1HSD11B1ALDH1A1KDM4EHPGD | |
| SCHEMBL8672473 | 0.86 | L3MBTL1 (0.56) | NPC1TDP1L3MBTL1HSD11B1ALDH1A1 | |
| SCHEMBL4815795 | 0.85 | NPC1 (0.51) | NPC1TDP1L3MBTL1HSD11B1ALDH1A1 | |
| SCHEMBL2001609 | 0.85 | L3MBTL1 (0.63) | L3MBTL1HSD11B1ALDH1A1KDM4EHPGD | |
| SCHEMBL8934952 | 0.85 | HSD11B1 (0.68) | L3MBTL1HSD11B1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102427729-A | Inhibitors of hepatitis c virus replication | MERCK SHARP & DOHME | 2012-04-25 | — | — | CN | claimed |
| WO-2025041809-A1 | METHOD FOR PRODUCING DEUTERATED COMPOUND | 国立大学法人九州大学 | 2025-02-27 | — | — | WO | disclosed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-08 | — | — | US | disclosed |
| US-20220111367-A1 | HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME | OSAKA UNIVERSITY (JP) | 2022-04-14 | — | — | US | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9284270-B2 | Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids | THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) | 2016-03-15 | — | — | US | disclosed |
| US-9284270-B2 | Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids | THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) | 2016-03-15 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011075607-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20100197960-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL, REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-08-05 | — | — | US | disclosed |
| US-20100197960-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL, REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-08-05 | — | — | US | disclosed |
| EP-1893573-B1 | INHIBITORS OF HCV REPLICATION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| CN-100569736-C | Produce the method for amino acid derivative | SOLVAY (BE) | 2009-12-16 | — | — | CN | disclosed |
| WO-2009030022-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2009-03-12 | — | — | WO | disclosed |
| CN-1768030-A | Process for producing amino acid derivatives | SOLVAY (BE) | 2006-05-03 | — | — | CN | disclosed |
| EP-0657454-A1 | Imidazopyridazines being angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197960-A1 | METHOD FOR THE ORGANOCATALYTIC ACTIVATION OF CARBOXYLIC ACIDS FOR CHEMICAL, REACTIONS USING ORTHOSUBSTITUTED ARYLBORONIC ACIDS | AOC2, AOC3, OXER1 | NPC1 3057/4885TDP1 2660/4885L3MBTL1 1802/4885 |
| US-20230172961-A1 | THERAPEUTICS FOR COVID-19 | ACE, ACE2, PNP | NPC1 1142/4885TDP1 192/4885L3MBTL1 1239/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NPC1 65/4885TDP1 3331/4885L3MBTL1 3763/4885 |
| US-20220111367-A1 | HYDROGENATION CATALYST FOR USE IN HYDROGENATING AMIDE COMPOUND AND METHOD FOR PRODUCING AMINE COMPOUND USING SAME | SUV39H2, SUV39H1, HRH3 | NPC1 4484/4885TDP1 3043/4885L3MBTL1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.